NVP-DPP728 dihydrochloride 

NVP-DPP728 dihydrochloride is a potent, selective and orally active dipeptidyl peptidase IV (DPP-IV) inhibitor with a K_i of 11 nM. NVP-DPP728 dihydrochloride can be used for the research of diabetes mellitus^[1][2].

Ki: 11 nM (DPP-IV) ^[1]

NVPDPP728 inhibits human and rat plasma DPP-IV (IC₅₀s: 5-10 nM) with >15 000-fold selectivity relative to DPP-II and a range of proline-cleaving proteases^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NVP-DPP728 (3.72 mg/kg; p.o.) inhibits DPP-IV and improves insulin secretion and glucose tolerance, probably through augmentation of the effects of endogenous GLP-1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

371.26

C₁₅H₂₀Cl₂N₆O

207556-62-5

N#CC1=CC=C(NCCNCC(N2[C@H](C#N)CCC2)=O)N=C1.[H]Cl.[H]Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. T E Hughes, et al. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry. 1999 Sep 7;38(36):11597-603.  [Content Brief]

  [2]. B Balkan, et al. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia. 1999 Nov;42(11):1324-31.  [Content Brief]